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1. Introduction 
Mesenchymal stem cells’ field has flourished lately. It is undoubted that MSC have the 
ability to repair several damaged tissues. Multipotent mesenchymal stromal cells (MSC) can 
be isolated and efficiently expanded from almost every single body tissue and has the ability 
of self-renewal and differentiation into various mesodermal cell lineages. MSC can provide 
effective treatments for a wide range of diseases and posses several applications in 
regenerative medicine such as tissue repair and gene delivery. In fact, relevant data have 
been generated in animal models of human diseases and some clinical trials are even being 
started. However, little is known about how MSC can repair. It is suggested that the MSC 
has pleiotropic actions releasing pro-survival factors to cytoprotective microvesicles. In this 
chapter, we will review and discuss the main conjectures on the mechanisms of action of 
MSC in animal and human contexts. 
2. Mesenchymal Stem Cells (MSC) biology: concept, terminology, sources, cell 
phenotype, gene profile and senescence  
The so called “stem cell” called “stem cell” is the cell that by definition has two main 
properties: 1) Asymmetric division and 2) Differentiation capacity. Not all cells in our body 
follow these two properties. 
In this sense, there are two main cells: embryonic stem cells and adult stem cells. For the 
purpose of this chapter, we will focus on adult stem cells.  
The existence of adult stem cell is now well accepted. Tissue repair after injury and also the 
continuous homeostatic self renewal of some tissue consolidate this idea (1).  
In 1970, Friendstein and collaborators described for the first time that bone marrow 
harbours not only hematopoetic stem cells (HSC), but also other type of cell that has 
clonogenic properties in vitro, characterizing these cells by their property to form fibroblast 
colonies in the primary passage in culture (CFU-F: colony-forming unit fibroblastic)(2). Later 
on, therapeutic approaches were approaches were achieved by using these cells in bone 
disorders (3, 4). 
Years later, Caplan and co-workers named these cells as mesenchymal stem cells (MSC) (5, 
6). In 1999, Pittenger et al demonstrated that these cells are multipotent stem cells with 
potential to differentiate into other cells from mesenchymal tissues (7).   
Others sources of mesenchymal stem cells have been described since then. MSC are not only 
found at bone marrow. Adipose tissue has also been demonstrated as a potential niche (8). 
In addition, dental pulp (9), limbus (10), amniotic membrane (11) amniotic fluid (12), kidney 
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(13) and several other organs may harbor mesenchymal stem cell populations. In culture, all 
these cells posses a fibroblast-like phenotype and share similarities in their 
immunophenotype and differentiation assays.  
Once it was seen that, several organs and tissue have MSC, the name needed to be 
standardized. In 2005, the International Society of Stem Cell Research (ISSCR) termed these 
cells as multipotent mesenchymal stromal cells for fibroblast-like plastic adherent cells 
isolated  from any organ (14). And if this cell follows the minimal criteria of stem cell, so this 
cell can be called mesenchymal stem cell. There are three main criteria in order to determine 
the indentity of MSC: 1) must have adherence to plastic;  2) expression of CD105, CD73 and 
CD90, and lack of expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and 
HLA-DR surface molecules; 3) must have differentiation potential (15). More recently, 
Caplan has suggested, due to its properties; to again rename MSC to “Medicinal Signaling  
Cells” because of its main mechanism of action (16). 
Despite this phenotype similarity, gene profile among all these cells may be different. A 
molecular signature of markers of stem lineage markers and genes regulating 
developmental and regenerative processes is more elucidative (17). Peroni et al, in a detailed 
work, demonstrated that MSC from bone marrow have an identical molecular profile when 
compared to MSC from adipose tissue. Nevertheless, a difference in some genes expression 
may happen with culture conditions (17). However, some authors suggest that the site of 
origin of MSC leads to the expression of specific genes pathways. A comparative study of 
MSC from bone marrow and MSC from umbilical cord from Panepucci et al showed that 
there are some gene that are more expressed in one cell than another. For instance, genes 
related to antimicrobial activity and osteogenesis are more expressed in MSC from bone 
marrow; and genes related to matrix remodeling and angiogenesis are more expressed in 
MSC from umbilical cord (18). Proteome analysis of MSC also demonstrated a full list of 
proteins expressed by MSC as described by Park et al (19). 
In fact, MSC population is not spread all over the organ. To maintain its properties, stem 
cells are located at niches. Niche is an environment defined by extracellular matrix and 
others cells that secrete several factors to maintain stem cells under its undifferentiated state 
and quiescence, since adult stem cells are highly sensitive to external signals (20-22).  Thus, 
if the niche is not well regulated, for instance in a pathologic state, stem cells may not react 
as expected: to repair and maintain homeostasis. Moreover, a problem in this delicate 
balance between stem cells and its niche may also lead to cancer (23). 
The niche per se is very important; however stem cell stability is also necessary.  DNA 
damage in melanocyte stem cells induce premature differentiation, leading to apoptosis and 
senescence (24). Regarding that cellular aging may be due to DNA alterations; this is 
probably an explanation for the inverse correlation between age and adult stem cell 
population and its functionality (25). 
Despite all efforts, the potential niche for adult stem cell in vivo has not yet been defined. A 
perisvascular niche is one possible place (26, 27). Some authors support the idea that 
mesenchymal stem cells are located throughout the body as pericytes, since it is related to 
tissue homeostasis and blood vessels stabilization (27). In this sense, da Silva Meirelles et al 
showed the direct correlation between the quantity of blood vessel and stem cells (28). 
3. MSC therapy and its ability to repair several diseases 
As previously written, all tissues per se have the capacity of homeostasis maintenance. 
However, after an injury, this process is somehow disturbed by inflammation or by 
extracellular matrix disruption, not allowing proper stem cell action.  
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Thus, in a way to assist the repair process, several works have focused on the administration 
of exogenous stem cells. Surprisingly, the administration of adult stem cell in several 
experimental diseases have showed to improve in its clinical outcome and moreover 
amelioration of tissue architecture.  
However, the mechanism of action that leads to this improvement is not well defined. 
Fusion of dying cells with MSC, differentiation of MSC to other cell types or paracrine 
action, by secretion of several bioactive factors are the main mechanism of action suggested. 
New mechanisms have also been suggested with the knowledge of microRNA. These topics 
will be better explained in the next sections. 
3.1 Animals models of human diseases: kidney, heart, CNS, liver, lung and pancreas 
The main experimental models treated with mesenchymal stem cells are summarized in the 
next table (Table I). 
 
 
Experimental 
Model 
Cell 
(amount/way/time) 
Mechanism of Action 
suggested for better 
outcome of injury 
Reference 
Kidney 
Acute Kidney Injury 
Rat MSC, 2x105 cell/rat, 
e.v., 6h after ischemia-
reperfusion injury 
Immunomodulation 
 
(29) 
Microvesicles from 
human MSC, 15 
µg/animal, e.v., 3 days 
after glycerol 
administration 
mRNA and microRNA 
carried by 
microvesicles 
(30) 
MSC, 1x105 cell/mouse, 
intra-arterially, 30 min 
after inschemia-
reperfusion injury 
Paracrine action – 
VEGF, HGF, IGF-1 
secretion 
(31) 
Chronic Kidney 
Injury (remnant 
model) 
Rat MSC, 2x105 cell/rat, 
e.v., 2nd week after 5/6 
remnant model every 
other week until 8th 
week. 
Immunomodulation 
and paracrine action 
(32) 
Rat MSC, 1x105 cell/rat, 
e.v., 1 week after 5/6 
nephrotomy 
MSC engraftment and 
paracrine action 
(33) 
Chronic Kidney 
Injury (unilateral 
ureteral obstruction) 
Human MSC, 1x106 
cell/rat, intra-arterially, 
after ureter obstruction 
Immunomodulation (34) 
Glomerulonephritis 
Rat MSC, 2x106 
cell/rat, intra-arterially, 
2 days after Thy1.1 
administration 
Early results: paracrine 
effect 
Long-term results: 
maldifferentiation of 
MSC to adipocytes 
(35) 
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Experimental 
Model 
Cell 
(amount/way/time) 
Mechanism of Action 
suggested for better 
outcome of injury 
Reference 
Heart 
Myocarcial infarct 
model 
Swine MSC, 6x107
cell/swine, in situ at 
infracted area, two 
weeks after artery 
occlusion 
Engraftment at 
myocardium 
(36) 
   
CNS 
Spinal cord injury 
Human MSC, 1.5x105 
cell/rat, injury in situ, 
at time of surgery 
Immunomodulation 
and engraftment 
(37) 
Parkinson model 
Rat MSC, 1.106 cell/rat, 
intranasally, 3 days post 
surgery. 
Immunomodulation, 
anti-apoptotic effect 
and engraftment 
(38) 
   
Liver Liver Fibrosis (CCl4) 
Rat MSC, 3x106 
cell/rat, e.v., 42 days 
after CCl4 
administration 
Paracrine and anti-
apoptotic effect 
(39) 
   
Lung 
Acute Lung Injury 
(LPS) 
Mouse MSC, 1x105
cell/mouse, e.v., 2h 
after the first LPS 
inhalation 
Immunomodulation (40) 
Chronic Lung Injury 
(Bleomycin) 
Mouse MSC, 2.5x105
cell/mouse, e.v., 7 days 
after bleomycin 
administration.  
Engraftment, 
immunomodulation 
(41) 
   
Pancreas 
Diabetes 
Autoimmune 
(NOD animal) 
Mouse MSC, 1x105
cell/mouse, i.p. or e.v., 
NOD mice at 4 weeks 
old. 
Immunomodulation (42) 
Table I. Some pre-clinical data on MSC therapy 
3.2 Human trials with MSC 
Pre-clinical studies have stimulated human clinical trials. Searching for “adult stem cell” at 
Clinicalstrials.gov, nearly 3300 studies were found. Within these studies, 1530 are recruiting 
patients. Some of these clinical trials are related in Table II. 
These numbers are alarming. The real mechanism of action of MSC, as well as the long-term 
studies are not yet clarified. Despite it, others issues still hold doubts such as the amount of 
cells, site of injection, which cell is the best for each illness, which is the level of cell survival 
and engraftment, etc. These questions should be answered before clinical trials are started.  
However, completed clinical trials have demonstrated efficient amelioration on clinical 
outcomes. MSC therapy has been focused on graft versus host diseases (GvHD) (43), limb 
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ischemia (44), acute kidney injury (45), lung injury (46), myocardial infarction (47), etc. 
Safety and efficacy will be discussed next in this article. How MSC leads to this better 
clinical outcome, despite which disease is it, is described below.  
 
Study Condition Status 
Evaluation of Circulating Levels of 
Adult Stem Cells in the Peripheral 
Blood of Patients With Acute 
Decompensated Heart Failure and 
Following Stabilization, in 
Comparison With Healthy 
Volunteers NCT01027403 
Heart Failure Recruiting 
Adult Stem Cell Therapy in Liver 
Insufficiency NCT00147043 
Liver Cirrhosis Completed 
Safety Study of Adult Stem Cells to 
Treat Patients With Severe Leg 
Artery Disease NCT00913900 
Critical Limb Ischemia Recruiting 
Long-term Safety and Efficacy of 
Adipose-derived Stem Cells to Treat 
Complex Perianal Fistulas in Patients 
Participating in the FATT-1 
Randomized Controlled Trial 
NCT01020825 
Complex Perianal Fistula Recruiting 
Evaluation of PROCHYMAL[tm] 
Adult Human Stem Cells for 
Treatment-resistant Moderate-to-
severe Crohn's Disease 
NCT00482092 
Crohn's Disease Recruiting 
Autologous Mesenchymal Stem 
Cells From Adipose Tissue in 
Patients With Secondary Progressive 
Multiple Sclerosis NCT01056471 
Multiple Sclerosis Recruiting 
Mesenchymal Stem Cell Infusion as 
Prevention for Graft Rejection and 
Graft-Versus-Host Disease 
NCT00504803 
Hematological Malignancies Recruiting 
Intravenous Stem Cells After 
Ischemic Stroke NCT00875654 
Stroke Recruiting 
Induction Therapy With Autologous 
Mesenchymal Stem Cells for Kidney 
Allografts NCT00658073 
Renal Transplant Rejection Completed 
 
Table II. Some clinical trials ongoing 
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4. MSC mechanisms of action  
4.1 Differentiation  
Before talking about differentiation it is important to consider the two categories into which 
stem cells can be classified (according to their developmental status): embryonic and adult 
(postnatal). Each represents a diverse differentiation potential status and a different potential 
application. Embryonic stem are pluripotent cells isolated from the inner cells mass of 
blastocysts, and are capable of giving rise to cells found in all three germ layers of the embryo. 
They are considered to have the greatest range of differentiation potential. On the other hand, 
adult stem cells have the capacity renew tissue after trauma, disease, or aging. These cells are 
found in different scales of quantity and potentiality (uni-, di-, tri-, and multi-potent), and their 
differentiation status is related to cell plasticity, where cells of one type give rise to cells of 
another type, however closely related (cell flexibility) (48). Mesechymal stem cells are adult 
stem cells with reduced differentiation capacity and higher plasticity capacity. 
The differentiation and plasticity characteristics mentioned above exemplify the flexibility of 
MSC. It is well known that mesenchymal cells can shift from one differentiation pathway to 
another under modified external conditions, and can shift from quiescence to a proliferative 
state or that MSC differentiation can be reversed at least up to a certain stage (49, 50). MSCs 
have also been reported to differentiate into various epithelial cell types after systemic 
administration in vivo. Studies have shown that after bleomycin exposure, MSC lung 
engraftment was enhanced showing a small percentage of MSC localized to areas of lung 
injury. In addition, MSC also differentiated into type I pneumocytes (51) or assumed 
phenotypic characteristics of all major cell types in lung including fibroblasts, type I and 
type II epithelial cells, and myofibroblasts (52). MSCs have also been shown to differentiate 
into retinal pigment epithelial cells (53), skin epithelial cells (54) and tubular epithelial cells 
in kidney (55). 
Different techniques have been used for MSC differentiation: use of biological and 
pharmacological reagents (56-59); mechanical cues (60-62) and external mechanical and 
electrical forces (63-66). Both mechanical and electrical stimulation have been applied 
separately and combined with soluble factors to facilitate MSC differentiation (67).  
The criteria for differentiation need to be rigorously defined. It appears difficult to ascertain 
about differentiation process. Some markers are specific for certain cells; however they do 
not have functional relation.  In addition these markers are not unique to characterize a 
specific cell. Delorme et al have found that MSC express cytoskeletal proteins usually 
expressed in neural stem cells (nestin), hepatocytes (cytokeratin-8 and -18), biliary cells 
(cytokeratin-19), and sarcomeric muscle (troponins, a-C-actin), without the expression of 
proneural or neuronal, prohepatocytic, or myogenic key transcription factors (68). Although 
cytoskeletal markers remain adequate indicators of a differentiation pathways, there are 
numerous exceptions to the rule, such as the expression of cytokeratin-18 in vascular smooth 
muscle cells in the synthetic phase and other similar misleading expression factors as 
reported by Montzka (69). 
Some of the observed differentiations may also result from reprogramming. Dezawa and 
colleagues have shown that rodent and human bone marrow MSC can be reprogrammed 
into cells with skeletal muscle potential after specific treatment comprising first cytokines 
and then gene transfer of the notch intracellular domain (70). 
Differentiation induction can be also marked by the decline of one factor at the expense of 
the other, like runt-related transcription factor-2 (RUNX2) downregulation and peroxisome 
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proliferator-activated receptor-g (PPARγ) upregulation in the adipogenic condition, which 
remains to be tested at the single cell level (71). 
It has been shown that MSC of various species  may undergo myogenic differentiation 
(72, 73). In a mouse model of myocardial infarction it has been seen that MSCs are capable 
of engrafting in the site of injury and differentiating into cardiomyocyte-like cells 
expressing typical cardiomyocyte markers (74). Another study showed that in mice 
undergoing cisplatin-mediated acute renal failure, systemic injection of MSCs resulted in 
accumulation of MSC in the kidney and differentiation into tubular epithelial cells that 
exhibited the characteristic brush border of the proximal tubule cells (55). Besides, there 
have been a number of reports suggesting that MSC differentiate into epidermal 
keratinocytes and endothelial cells in vivo (75, 76).  In vivo, adipose-derived  MSC can 
migrate through the hemato-encephalic barrier after adhesion to the endothelium (77), 
and they can differentiate into neuroglial lineages after intraventricular in utero injection 
in rats (78). However, in humans there is no evidence concerning the neural regenerative 
potential of MSC. 
MSC obtained from different tissue sources show some differences regarding differentiation 
potential and gene expression profiles. Thus, it has become clear that the microenviroment 
in which MSCs are transplanted, growth factors and local cellular interactions, play a 
pivotal role in determining both MSC biology (survival, proliferation, and specific 
differentiation) and eventually a clinical measurable improvement.  
4.2 Fusion  
Cell fusion is a process that has an important biological role in the development, physiology 
and disease of multicellular organisms. For example, we have the zygote formation and 
organogenesis of various tissues, such as placenta, bone and skeletal muscle. There are 
different types of cell fusion: homotypic and heterotypic cell fusion. Homotypic fusion 
happens between cells of the same type; like fusion between myoblasts for the formation 
and growth of multinuclear myofibres and multinucleated cells during chronic 
inflammatory conditions. In a heterotypic cell fusion, which describes the fusion between 
cells of different lineages, we have stem cells, where in specific adult stem cells can be used 
for clinical therapy by introducing a nuclei or functional genes in aged or degenerating cells 
(79). Recent reports have indicated that stem cells can fuse with differentiated cells in a 
range of tissues, including the brain, kidney, heart, lung and liver.  
It’s known that inflammation promotes migration and infiltration of bone marrow-derived 
stem cells to sites of tissue injury. Moreover, inflammation also increases the frequency of 
stem cell fusion. In the brain, chronic inflammation cen cause an increase in spontaneous 
fusion events through the increase of cytokine levels, by activating immune cells or by 
damaging the blood brain barrier leading to increased permeability (80, 81). Mechanistically, 
it is important to note that lipid bilayer membranes do not spontaneously fuse,  and  that  
fusion  between  membranes involves  a  highly  intricate  choreography  of  lipids  and  
proteins.  Alterations in the cell membrane that are likely to occur during chronic 
inflammation and the concomitant production of a variety of cytokines may predispose 
certain cells to fusion events.  
Scolding et al hypothesized that endogenous factors associated with inflammation, such 
as tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma, may also directly 
activate stem cells and Purkinje cells to promote fusion. They demonstrated that fusion 
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between MSCs and cerebellar neurons can occur spontaneously in vitro, associated with a 
markedly higher incidence of the inflammatory mediators such as TNF-alpha and IFN-
gamma. The same group, has shown that human bone marrow-derived MSC also exhibit 
this potentially reparative action in vivo, fusing with Purkinje cells in the rodent 
cerebellum. These function events are also increased in the neuroinflammatory 
environment of experimental autoimmune encephalomyelitis (EAE), with no apparent 
loss in Purkinje cell numbers (82). 
To confirm this, previous reports have demonstrated fusion between rodent haematopoietic 
stem cells and rodent Purkinje cells, with increased levels occurring in the context of central 
nervous system (CNS) or systemic inflammation (80). In another CNS study, Bae et al 
demonstrated that bone marrow-derived MSC/Purkinje neuron fusion-like events develop 
into electrically active neurons with functional synaptic formation in the cerebellum of mice 
with neurodegeneration. Thus, MSCs may be able to integrate into the CNS and contribute 
to the essential properties of mature neurons (83). 
Alvarez-Buylla et al used a simple method based on Cre/lox recombination to detect cell 
fusion events, demonstrated that bone-marrow-derived cells (BMDCs) fuse spontaneously 
with neural progenitors in vitro. Furthermore, bone marrow transplantation demonstrates 
that BMDCs fuse in vivo with hepatocytes in liver, Purkinje neurons in the brain and cardiac 
muscle in the heart, resulting in the formation of multinucleated cells, suggesting that 
genetic material derived from BMDCs contribute through cell fusion to the survival and 
function of these cells (84).  
Adnan and colleagues have show that BMDCs can fuse with a long-lived progenitor or 
intestinal stem cell population of gamma-irradiated damaged intestinal epithelium and can 
also fuse with tumor epithelium. Fusion of BMDCs with progenitors or stem cells may play 
an important role in the regeneration of damaged tissue, and the observation that BMDCs 
can fuse with tumor epithelium is an important finding  also, since  the study of this event 
will enhance the understanding of the biology of tumorigenesis and may provide a novel 
strategy for the development of anticancer therapies (85). 
Other clear beneficial effects of heterotypic cell fusion of BMDCs with other cells types have 
been demonstrated in a mouse model of a lethal liver disease in which the enzyme 
fumarylacetoacetate hydrolase is absent, and a large numbers of wild-type BMDCs fused 
with mutant liver cells corrected the metabolic deficiency and ameliorated the disease 
phenotype (86). 
These studies demonstrate that stem cells are able to fuse with cells of different tissues. 
However, additional studies in animal models will be required to determine whether this 
fusion can be used in reparative cell therapy. 
4.3 Paracrine factors 
Although there are many ways through which stem cells may ameliorate injury, the main 
mechanism is considered is through paracrine and endocrine functions.  Today, a wide 
range of cytokines and factors are known to be involved in the beneficial interaction 
between MSC and other cells. 
4.3.1 Immunomodulation 
Among all theories regarding the paracrine action for MSCs, by far the most explored and 
discussed by research is immunomodulation. Considering the inflammatory nature of most 
injuries, studies have indicated that the predominant role of MSCs in resolving tissue 
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damage relies on toning down inflammation in specific sites of injury. While there are many 
factors suggested by literature, the main and most frequently pointed out factors and 
regulated immune cells are discussed ahead. 
Monocytes/Macrophages 
Since macrophages are one of the main cells responsible for cytokine production in injury 
sites, these cells are main focus points when immunomodulation is considered. Recent 
studies have indicated an important role in mesenchymal stem cell monocyte and 
macrophage immunomodulation. Maggini et al. amongst others have demonstrated that 
MSCs inhibit macrophage pro-inflammatory cytokine production, i.e. TNF-a, IL-6 and IFN-g 
(87-89). MSC also stimulate anti-inflammatory cytokine, IL-10 and IL-12p40 production (87, 
88). This way, immune cell activation and the local inflammatory process is contained, 
reducing tissue damage.  MSC also enhance apoptotic cell phagocytosis which is important 
in clearing injury sites. In addition, these cells inhibit monocyte derived dendritic cell 
differentiation (90). These effects seem to be due mainly to MSC-derived PGE2 secretion, 
which has direct effects on macrophage activation. 
Dendritic Cells 
Dendritic cells (DCs) have essential roles in antigen presentation and lymphocyte profile 
modulation. MSC are capable of inhibiting DC maturation through cell to cell contact and 
PDGE2 and IL-6 production, as seen through downregulated expression of CD1a, IL-12p70, 
MHC class II molecules, CD80 and CD86 (91, 92).  As T cells depend importantly on antigen 
presenting cells to become activated, dendritc cell modulation is considered a possible 
mechanism for T lymphocyte tolerance induction. In addition, MSC treatment also impacts 
DC migration, as seen in reduced CCR7 expression and reduced migration in response to 
CCL19 (92). Also, mature type 1 DCs decrease TNF-a production and type 2 DCs increase 
IL-10 expression which may also induce Th2 profile lymphocytes (93).  
T Lymphocytes 
Research has shown that T lymphocyte modulation has an important role in the therapeutic 
character of MSC. For starters, in a disease setting, a considerable percentage of exogenous 
MSCs tend to accumulate in the spleen and lymph nodes, in particular around immune cells 
such as DCs, T and B lymphocytes, suggesting cell-specific interaction (94). MSCs  are not 
considered to display important allogenic properties, being immune-privileged, due to low 
HLA -DR and costimulatory molecule expression and its basic immunomodulatory 
properties, although a full consensus does not exist towards the degree in which this 
happens (95, 96). In vitro, MSC inhibit phytohemagglutinin mitogen-induced and mixed 
lymphocyte reaction allo-antigen driven T cell proliferation (97-99). This is done by both 
cell-to-cell contact and humoral factors in specific, secreting IDO and Galectin-1. These stem 
cells also decrease TNF-a and IFN-g T cell production and raise IL-10 secretion, possibly 
mediated by IDO, PGE2 and B7-H amongst other molecules (100-102). MSCs also induce 
Th2 type lymphocyte and T regulatory cell differentiation through, HLA-G5 and other 
molecules (103-105). 
B lymphocytes 
Although many works have associated MSC and T lymphocyte regulation, few have 
indicated a direct role in B lymphocyte function, and many published studies are 
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controversial. Yanfei et al have shown that B lymphocytes have decreased proliferation and 
antibody production when cultivated with MSC regulated allogenic DCs (106). In addition, 
other studies suggest that MSC directly inhibit B lymphocyte plasma cell differentiation 
through humoral factors (107, 108). On the other hand, other studies indicate that 
mesenchymal stem cells induce B-cell proliferation and differentiation into plasmocytes, 
when stimulated with a Toll-like receptor 9 agonist (109). These different results are 
probably due to the different stimuli used and its detailed effect on B cell outcome is still to 
be discovered. 
NK / iNKT Cells 
Little information is still known on MSC-mediated NK / invariant natural killer T Cells 
(iNKT) in comparison to other cell types. Studies demonstrate that MSCs inhibit NK and 
iNKT cell activation and IFN-g production by secretion of mediators as HLA-G5 and PGE2 
respectively (110, 111). It is also important to mention that NK cells induce MSC lysis, 
probably due to low HLA class I molecule expression (112, 113). Also, important 
consideration needs to be given to MSC effects on the immune system in regards to tumor 
surveillance, due to NK cell inhibition (114). 
4.3.2 Angiogenic factors  
Angiogenic support provided by MSC can be considered one more supportive effect, since 
the re-establishment of blood supply is fundamental for recovery of damaged tissues. The 
pro-angiogenic effect of MSC have been demonstrated in several studies in vitro and in vivo 
(115-118). 
It is known that MSCs express and secrete Stromal cell-derived factors 1 (SDF-1), vascular 
endothelial growth factor (VEGF), and other cytokines important for angiogenesis (Basic 
Fibroblast Growth Factor (bFGF); Matrix metalloproteinases (MMPs). VEGF has been identified 
as a key component in the development of blood vessels, but VEGF alone may be 
insufficient to achieve functional and mature development of the vasculature. VEGF-
induced vessels are often leaky and do not connect appropriately to the existing vasculature 
(119, 120). SDF-1 activity is essential for endothelial cell survival, vascular branching and 
pericyte recruitment (121). Interestingly, SDF-1a is not only a mobilization signal capable of 
recruiting CXCR4- positive progenitor cells into hypoxic tissues but also a retention signal 
for angiocompentent bone marrow-derived stem cells. It also recruits pericytes and smooth 
muscle cells to stabilize and mature newly formed blood vessels (122, 123). Thus, SDF-1 has 
been shown to augment neovascularization by the acceleration of endothelial progenitor cell 
(EPC) recruitment into ischemic foci (122, 124). In addition, VEGF is one of the powerful 
angiogenic cytokines that can also mobilize EPCs from bone marrow and inhibit EPC 
apoptosis (125). In the mouse ischemic hind limb model, VEGF-A-mediated angiogenesis 
partly depends on the activation of the SDF-1—CXCR4 pathway (124). Taken together, the 
chemokine SDF-1 likely plays a pivotal role in ASC-mediated angiogenesis (126). 
Interestingly, studies have demonstrated that mesenchymal stem cells have the same 
angiogenesis property. Shintani et al demonstrated that implantation of autologous bone 
marrow mononuclear cells into ischemic skeletal muscles successfully augmented 
angiogenesis and collateral vessel formation in both animal studies and human trials (127-
129). The same group found that implantation of ASC significantly augmented 
angiogenesis in a mouse model of hind limb ischemia, by release chemokines such as 
SDF-1 (126). Kim et al. demonstrated in a preliminary clinical trial that implantation of 
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human cord blood-derived mesenchymal stem cells enhanced angiogenesis and collateral 
vessel formation in human cases with Buerger’s disease (130). Kamihata and colleagues 
have reported that bone marrow mononuclear cells that survived engrafting can 
synthesize angiogenic factors such as VEGF, bFGF, and angiopoietin-1 to induce 
angiogenesis in the ischemic myocardium (128). 
In summary, engrafting MSC in clinical therapy has a beneficial effect, which may be 
attributable to paracrine action. MSC secrete a number of angiogenic factors and stem cell 
homing factor that are able to re-establishment of blood supply, being this fundamental for 
the recovery of damaged tissues. 
4.3.4 Anti-apoptotic factors  
An important role in MSC-mediated protection is its inhibition of tissue apoptosis and 
augmentation of tissue turnover. Studies show that MSC are capable of inhibiting apoptosis 
in kidney, liver and brain injuries (30, 131-133). Recent evidence shows that this is done 
through increasing prosurvival factors as Akt expression in injured cells (55), BDNF and 
growth factors as IGF, VEGF and HGF expression which inhibit apoptosis and stimulate cell 
proliferation (134, 135). Together, this dynamic permits high cell turn-over, renewing 
damaged cells and decreasing excessive cell death, thus restoring normal tissue physiology.  
4.3.5 Anti-oxidative factors 
It is well known that MSC mediate tissue repair through paracrine mechanisms. Besides 
mediating directly in the inflammatory process, some studies have suggested that MSC also 
posses anti-oxidative characteristics. MSC have been observed to produce many anti-
oxidative mediators such as IGF, PDGF, superoxide dismutase (SOD), HGF and IL-6 (136-
139). MSC-conditioned media has also been seen to contain these anti-oxidative factors 
including G-CSF, GM-CSF and IL-12, as reviewed by Kim et al (140). In addition, evidence 
has supported that MSC and its conditioned media respectively decrease oxidative damage 
in culture when fibroblast cells are exposed to oxidative damage-inducing environments 
such as UVB (141) or tert-butyl hydroperoxide (tbOOH) (142).  
In addition, research indicates that MSC posses not only considerable ability to support 
oxidative stress by producing anti-oxidative mediators, but may actually be stimulated by 
hipoxia-induced ROS (reactive oxigen species). During oxidative stress, MSC seem to have 
increased proliferation and migration mediated by the Akt and Erk pathways and platelet-
derived growth factor receptor-β (PDGFR- β) phosphorylation (143, 144). This however is still 
controversial. Other studies indicate that oxidative stress correlates with MSC senescence (145, 
146). These different results may be consequent to different ROS inductors, and consequently, 
different levels of ROS production and enviromental contributing factors envolved. 
4.4 Microvesicles and miRNA  
The paracrine action of MSC is now well accepted. In this sense, administration of conditioned 
medium of stem cell in an animal model of kidney injury has demonstrated to improve in 
clinical parameter outcomes correlated with decreased apoptosis and  ameliorated histological 
parameters. Despite the bioactive molecules secreted by MSC, Bruno et al have showed that 
inside the conditioned medium also there are some microvesicules.  
These microvesicles (MVs) are circular membranes fragments that shed from the cell surface 
membrane carrying protein and lipids from the membranes of the cells from which they 
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originate. Besides this, MVs may also carry mRNA and microRNA stablishing a 
communication between one cell and another (147). Shedding of microvesicles is a 
physiologic process, however some stress conditions lead to an increase in the number of 
MV shed (148). 
Camussi’s group has described that mesenchymal stem  cells are able to shed microvesicles, 
and moreover, these MVs carry mRNA and microRNA leading to amelioration of acute and 
chronic experimental models of renal injury, accelerating regeneration of hepatectomized 
rats and activating endothelial cells (30, 149-151). 
5. Long term aspects of MSC therapy: cancer, immunosuppression or 
maldifferentiation?  
The majority of pre-clinical and clinical studies, which are going on, are incipient. They 
analyzed the results of treatment in few months or years, not allowing long-term analysis. In 
these early results, MSC therapy has not shown adverse effects, being designated safe by FDA 
(152). Thus it is difficult to tell if MSC treatment per se may lead to cancer. Nevertheless, 
several studies have showed that MSC after infusion do not engraft in any tissue, emphasizing 
the paracrine mechanism of action (152). However, if the treatment is continuous or the MSC 
administration is repeated, MSC can be found in the injured tissue (32). When MSC is 
engrafted or even when there is an in situ administration, MSC may maldifferentiate. In a 
model of glomerulonephritis, MSC maldifferentiate to adipose cells in the kidney (35). In situ 
administration of human autologous stem cell therapy in a patient with lupus nephritis has 
induced angiomyeloproliferative lesions at the sites of injection and hematuria (153). 
All bioactive molecules secreted by MSC are prone to stimulate cancer cells to proliferate 
and migrate. Some works correlate MSC to suppression of tumor growth, others to 
supporting it. Several questions may be related to its discrepancy: animal host, timing of 
injection of MSC, differences in tumor models, etc (154). In addition, MSC may differentiate 
to tumor associated fibroblast (TAF), cells that support tumor growth (155). Thus, MSC 
therapy should exclude patients with cancer family history.  
Also, the immunossupression level of MSC therapy cannot be controlled. Once MSC are 
injected endovenously, immunossupression is achieved. MSC therapy may compromise the 
host’s defense against infections agents (156).  
6. Final considerations 
Many advances have been made in the field of mesenchymal stem cells. Nowadays much is 
known about what the MSC is and how is the mechanism of action. Currently, existing 
therapies administered exogenous MSC to treat several diseases. Perhaps, a deeper 
knowledge on endogenous stem cells may bring advances on cell therapy. To activate 
endogenous stem cells, via stimulation of the niche is an interesting therapeutic perspective. 
In addition, try to understand what happens to this endogenous stem cell in pathological 
state is one of the highlights to be discovered.  
In the conventional therapy - administration of exogenous MSC - many issues are yet to be 
solved: amount of injected MSC, the best route of administration, the culture conditions 
which are not standardized with the use of materials of animal origin, which is the best 
source for these cells, etc.  In conclusion, the field of MSC is very fruitful and still requires to 
be further studied.  
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